CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

This trial tests CER-1236, a new type of immune cell therapy for acute myeloid leukemia (AML) — a fast-moving blood cancer. CER-1236 uses engineered immune cells designed to recognize and attack leukemia cells. **You may be eligible if...** - You have been diagnosed with AML or a pre-leukemia condition called MDS/AML (with 10–19% leukemia cells in the bone marrow) - Your blood lymphocyte count is sufficient for collecting immune cells - You have a good performance status (ECOG 0 or 1) **You may NOT be eligible if...** - You have previously received a permanently gene-modified cell product (such as a prior CAR-T therapy) - There is no detectable leukemia in your bone marrow before any bridging therapy - You have an active autoimmune disease or have been treated for one within the last 2 years (exceptions apply for well-controlled thyroid disease or type 1 diabetes) Talk to your doctor to see if this trial is right for you.